STAR^® technology offers a very attractive way to rapidly identify stable, high producing mammalian cell clones, and can be used with important protein production cell lines such as CHO-K1 and CHO-DG44 to increase production of antibodies and therapeutic proteins.

To obtain stable cell lines that produce a protein of interest at high levels, often a large amount of clones have to be screened and analyzed. This whole process is time consuming, cost ineffective and resource demanding. With Crucell’s STAR^® technology only a few clones (between 30 and 50) need to be screened and analyzed to obtain a high producing cell line. Crucell’s STAR^® technology is therefore a very attractive way to rapidly identify stable high producing mammalian cell lines.

STAR^® technology supports high yield antibody & protein production. Using Crucell’s STAR^® technology, high levels of protein can be generated. This has been demonstrated in several CHO derivatives for several proteins and different antibodies. Under standard non-optimized cell culture conditions using commercially available medium, specific productivity levels ranging between 25 and 70 pg /cell/day are easily achieved with screening of only up to 50 clones. Therefore Crucell’s STAR^® technology is also ideal for stable bulk transfections to rapidly obtain adequate levels of protein for immunization, target discovery processes, protein characterization, or optimization and validation of downstream processes such as protein purification.